Form 4: Aclaris Therapeutics Interim CEO Neal Walker Reports Stock Transactions
SEC Form 4 Filing
Neal Walker, Interim President and CEO of Aclaris Therapeutics, reports the vesting of restricted stock units and subsequent tax withholding of shares.
Summary
- On September 1, 2024, Neal Walker, Interim President and CEO of Aclaris Therapeutics, had restricted stock units vest, resulting in the acquisition of 9,466 shares of common stock.
- Simultaneously, the company withheld 2,722 shares at a price of $1.18 to cover tax obligations related to the vesting of these restricted stock units.
- Following these transactions, Walker directly owns 1,362,897 shares of Aclaris Therapeutics common stock and 75,734 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation and does not inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 09/01/2024 | Date of stock transactions: vesting of restricted stock units and tax withholding. |
| 09/04/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.